Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT06900829Recruiting
HIV testing program for European hospitals
This trial helps hospitals find undiagnosed HIV by improving testing and care. It supports healthcare teams to identify HIV in people with certain conditions and ensures those diagnosed get connected to treatment.
GhentAges 18 years+ - NCT06900920RecruitingPhase 3
Study of TQB3473 tablets for adults with chronic immune thrombocytopenia
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Hefei, AnhuiAges 18–75 - NCT06901687RecruitingPhase 2
Home brain stimulation for depression in MS
This study tests whether a special, gentle brain stimulation device you can use at home (called tDCS) can help improve depression symptoms in people with multiple sclerosis. You will be supervised over video during the sessions to make sure everything goes smoothly.
New York, New YorkAges 18–65 - NCT06902012RecruitingPhase 1/Phase 2
Second infusion of CAR-T based on ctDNA for large B-cell lymphoma
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
Guangzhou, GuangdongAges 18 years+ - NCT06902597Recruiting
Sarcopenia and nerve damage in type 1 diabetes: a pilot study
This study looks at whether muscle loss (sarcopenia) is related to diabetic nerve damage in adults with type 1 diabetes. If you join, you will help researchers understand this connection better.
Rome, LazioAges 50–80 - NCT06902844Recruiting
Eque-cel for lupus that has not responded to other treatments
This trial tests a new cell therapy called eque-cel for people with lupus that has come back or is not controlled by standard treatments. It aims to see if this therapy can reduce lupus activity and improve symptoms.
Wuhan, HubeiAges 18 years+ - NCT06903780Recruiting
Survey on biologic treatments for severe asthma
This study surveys patients who have been on a biologic treatment for severe asthma for at least 6 months but not longer than 18 months. It aims to understand their experience, including those who did not respond well to the treatment.
Exeter, DevonAges 18 years+ - NCT06903884RecruitingPhase 3
Diquafosol eye drops for moderate-to-severe eye allergy
This trial tests a new eye drop called diquafosol for people with a severe, active eye allergy called vernal keratoconjunctivitis. It aims to see if the drops can calm the allergy and help heal the surface of the eye.
Hong KongAges 6 years+ - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT06906497RecruitingPhase 4
Lebrikizumab for moderate-to-severe eczema
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
Folsom, CaliforniaAges 18 years+ - NCT06906549RecruitingPhase 4
Testing a lower dose of rituximab every 6 months for rheumatoid arthritis
This study tests whether a lower dose (200 mg) of rituximab given every 6 months is effective for maintaining control of rheumatoid arthritis. It is for people who are already on rituximab maintenance therapy and have low to moderate disease activity.
StrasbourgAges 18 years+ - NCT06907056RecruitingPhase 4
A study on a simpler HIV medication combination
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
Mexico City, Mexico CityAges 18–70 - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT06908421Recruiting
Smart device and inhaler for better asthma control
This study tests if using a small smart device with your Trimbow inhaler helps you use it correctly and take it as prescribed. It is for people with asthma who already use Trimbow.
Hvidovre, Capital RegionAges 18 years+ - NCT06908629Recruiting
Helping Detroit cancer survivors with social needs
This study looks at how social needs (like finding enough food) affect cancer survivors in the Detroit area. If you join, researchers will work to connect you with resources that might help.
Detroit, MichiganAges 18 years+ - NCT06909253Recruiting
Study of ravulizumab for generalized myasthenia gravis
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
BydgoszczAges 18 years+ - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75 - NCT06909877RecruitingPhase 1/Phase 2
Study of HH2853 for relapsed or refractory peripheral T-cell lymphoma
This trial tests an experimental drug, HH2853, for people with certain types of T-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
Chengdu, ChengduAges 18–75 - NCT06910124RecruitingPhase 2
Testing linvoseltamab with lenalidomide for multiple myeloma
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
Miami, FloridaAges Any age - NCT06910969Recruiting
Telehealth support for chronic graft-versus-host disease
This trial offers a group telehealth program for adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The program aims to help manage symptoms and improve quality of life.
Miami, FloridaAges 18 years+ - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06913907RecruitingPhase 4
Methotrexate injection for new rheumatoid arthritis patients
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
Shinjuku-ku, TokyoAges 18 years+ - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.